Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease
October 07, 2021 08:00 ET
|
Acumen Pharmaceuticals, Inc.
ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Enrollment of early Alzheimer’s...
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights
August 16, 2021 16:05 ET
|
Acumen Pharmaceuticals, Inc.
Acumen’s investigational drug, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trialsInitiated...
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
June 30, 2021 22:44 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a...